X4 PHARMACEUTICALS, INC Operating Lease, Payments
X4 PHARMACEUTICALS, INC (XFOR) reported Operating Lease, Payments of $287.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-06
- X4 PHARMACEUTICALS, INC operating lease, payments for the quarter ending 2026-06-30 was $287.00K, a 18.93% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, payments for the quarter ending 2026-03-31 was $287.00K, a 17.53% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, payments for the quarter ending 2025-12-31 was $333.00K, a 3.48% decline year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, payments for the quarter ending 2025-09-30 was $363.00K, a 5.22% increase year-over-year.
- X4 PHARMACEUTICALS, INC operating lease, payments for fiscal 2025 was $1.40M, a 1.53% increase from fiscal 2024.
- X4 PHARMACEUTICALS, INC operating lease, payments for fiscal 2024 was $1.38M, a 0.58% decline from fiscal 2023.
- X4 PHARMACEUTICALS, INC operating lease, payments for fiscal 2023 was $1.39M, a 2.29% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC operating lease, payments for fiscal 2022 was $1.35M, a 7.72% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $287.00K 10-Q · filed 2026-08-06 | $574.00K 10-Q · filed 2026-08-06 | $907.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $287.00K 10-Q · filed 2026-05-06 | $620.00K derived: sum of 2 quarters · filed 2026-05-06 | $983.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $696.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.05M derived: sum of 3 quarters · filed 2026-08-06 | $1.40M 10-K · filed 2026-03-17 |
| 2025-09-30 | $363.00K 10-Q · filed 2025-11-05 | $717.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.06M 10-Q · filed 2025-11-05 | $1.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $354.00K 10-Q · filed 2026-08-06 | $702.00K 10-Q · filed 2026-08-06 | $1.05M derived: sum of 3 quarters · filed 2026-08-06 | $1.39M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $348.00K 10-Q · filed 2026-05-06 | $693.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.04M derived: sum of 3 quarters · filed 2026-05-06 | $1.38M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $690.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.03M derived: sum of 3 quarters · filed 2026-03-17 | $1.38M 10-K · filed 2026-03-17 |
| 2024-09-30 | $345.00K 10-Q · filed 2025-11-05 | $688.00K derived: sum of 2 quarters · filed 2025-11-05 | $1.03M 10-Q · filed 2025-11-05 | $1.38M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | $343.00K 10-Q · filed 2025-08-08 | $687.00K 10-Q · filed 2025-08-08 | $1.03M derived: sum of 3 quarters · filed 2026-03-17 | $1.38M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $344.00K 10-Q · filed 2025-05-01 | $692.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.04M derived: sum of 3 quarters · filed 2026-03-17 | $1.38M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $693.00K derived: sum of 2 quarters · filed 2026-03-17 | $1.04M derived: sum of 3 quarters · filed 2026-03-17 | $1.39M 10-K · filed 2026-03-17 |
| 2023-09-30 | $345.00K 10-Q · filed 2024-11-13 | $690.00K derived: sum of 2 quarters · filed 2024-11-13 | $1.04M 10-Q · filed 2024-11-13 | $1.38M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-06-30 | $345.00K 10-Q · filed 2024-08-08 | $691.00K 10-Q · filed 2024-08-08 | $1.03M derived: sum of 3 quarters · filed 2025-03-26 | $1.36M derived: sum of 4 quarters · filed 2025-03-26 |
| 2023-03-31 | $346.00K 10-Q · filed 2024-05-07 | $686.00K derived: sum of 2 quarters · filed 2025-03-26 | $1.02M derived: sum of 3 quarters · filed 2025-03-26 | $1.36M derived: sum of 4 quarters · filed 2025-03-26 |
| 2022-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $674.00K derived: sum of 2 quarters · filed 2025-03-26 | $1.01M derived: sum of 3 quarters · filed 2025-03-26 | $1.35M 10-K · filed 2025-03-26 |
| 2022-09-30 | $334.00K 10-Q · filed 2023-11-09 | $672.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.01M 10-Q · filed 2023-11-09 | $1.35M derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-06-30 | $338.00K 10-Q · filed 2023-08-10 | $680.00K 10-Q · filed 2023-08-10 | $1.02M derived: sum of 3 quarters · filed 2024-03-21 | $1.33M derived: sum of 4 quarters · filed 2024-03-21 |
| 2022-03-31 | $342.00K 10-Q · filed 2023-05-04 | $682.00K derived: sum of 2 quarters · filed 2024-03-21 | $996.00K derived: sum of 3 quarters · filed 2024-03-21 | $1.28M derived: sum of 4 quarters · filed 2024-03-21 |
| 2021-12-31 | $340.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $654.00K derived: sum of 2 quarters · filed 2024-03-21 | $934.00K derived: sum of 3 quarters · filed 2024-03-21 | $1.26M 10-K · filed 2024-03-21 |
| 2021-09-30 | $314.00K 10-Q · filed 2022-11-03 | $594.00K derived: sum of 2 quarters · filed 2022-11-03 | $917.00K 10-Q · filed 2022-11-03 | $3.77M derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-06-30 | $280.00K 10-Q · filed 2022-08-04 | $603.00K 10-Q · filed 2022-08-04 | $3.46M derived: sum of 3 quarters · filed 2023-03-21 | $3.94M derived: sum of 4 quarters · filed 2023-03-21 |
| 2021-03-31 | $323.00K 10-Q · filed 2022-05-12 | $3.18M derived: sum of 2 quarters · filed 2023-03-21 | $3.66M derived: sum of 3 quarters · filed 2023-03-21 | $3.90M derived: sum of 4 quarters · filed 2023-03-21 |
| 2020-12-31 | $2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $3.34M derived: sum of 2 quarters · filed 2023-03-21 | $3.58M derived: sum of 3 quarters · filed 2023-03-21 | $3.82M 10-K · filed 2023-03-21 |
| 2020-09-30 | $479.00K 10-Q · filed 2021-11-04 | $721.00K derived: sum of 2 quarters · filed 2021-11-04 | $963.00K 10-Q · filed 2021-11-04 | $1.23M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-06-30 | $242.00K 10-Q · filed 2021-08-03 | $484.00K 10-Q · filed 2021-08-03 | $754.00K derived: sum of 3 quarters · filed 2022-03-17 | $1.02M derived: sum of 4 quarters · filed 2022-03-17 |
| 2020-03-31 | $242.00K 10-Q · filed 2021-05-06 | $512.00K derived: sum of 2 quarters · filed 2022-03-17 | $780.00K derived: sum of 3 quarters · filed 2022-03-17 | $1.05M derived: sum of 4 quarters · filed 2022-03-17 |
| 2019-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $538.00K derived: sum of 2 quarters · filed 2022-03-17 | $804.00K derived: sum of 3 quarters · filed 2022-03-17 | $1.01M 10-K · filed 2022-03-17 |
| 2019-09-30 | $268.00K 10-Q · filed 2020-11-05 | $534.00K derived: sum of 2 quarters · filed 2020-11-05 | $737.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $266.00K 10-Q · filed 2020-08-04 | $467.00K 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $201.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |